Humana Inc. (NYSE:HUM) Shares Sold by Atlas Brown Inc.

Atlas Brown Inc. lessened its position in Humana Inc. (NYSE:HUMGet Rating) by 0.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,953 shares of the insurance provider’s stock after selling 43 shares during the period. Humana comprises about 2.0% of Atlas Brown Inc.’s portfolio, making the stock its 7th largest holding. Atlas Brown Inc.’s holdings in Humana were worth $4,191,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. raised its stake in Humana by 42.3% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 74 shares of the insurance provider’s stock worth $35,000 after acquiring an additional 22 shares during the period. Quadrant Capital Group LLC grew its stake in Humana by 3.0% during the 1st quarter. Quadrant Capital Group LLC now owns 845 shares of the insurance provider’s stock worth $368,000 after buying an additional 25 shares during the last quarter. Dorsey & Whitney Trust CO LLC lifted its stake in shares of Humana by 3.5% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 730 shares of the insurance provider’s stock worth $318,000 after acquiring an additional 25 shares in the last quarter. CVA Family Office LLC grew its holdings in Humana by 12.8% in the 2nd quarter. CVA Family Office LLC now owns 220 shares of the insurance provider’s stock worth $103,000 after buying an additional 25 shares in the last quarter. Finally, Allworth Financial LP lifted its position in shares of Humana by 10.9% during the 2nd quarter. Allworth Financial LP now owns 255 shares of the insurance provider’s stock valued at $119,000 after acquiring an additional 25 shares during the last quarter. Institutional investors own 93.50% of the company’s stock.

Analyst Ratings Changes

HUM has been the topic of several analyst reports. Truist Financial boosted their price target on shares of Humana from $550.00 to $570.00 and gave the stock a “hold” rating in a research report on Friday, September 16th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Humana from $450.00 to $514.00 in a research report on Thursday, July 28th. Oppenheimer raised their price objective on shares of Humana from $520.00 to $550.00 and gave the company an “outperform” rating in a research note on Friday, September 16th. Morgan Stanley raised shares of Humana from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $494.00 to $549.00 in a research report on Tuesday. Finally, SVB Leerink lifted their target price on shares of Humana from $535.00 to $540.00 and gave the stock an “outperform” rating in a research note on Thursday, July 28th. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $519.28.

Humana Price Performance

Shares of Humana stock traded down $11.80 during midday trading on Friday, reaching $482.11. The company had a trading volume of 42,876 shares, compared to its average volume of 868,719. The stock has a fifty day simple moving average of $487.67 and a 200 day simple moving average of $460.98. The company has a current ratio of 1.53, a quick ratio of 1.53 and a debt-to-equity ratio of 0.73. Humana Inc. has a 1-year low of $351.20 and a 1-year high of $514.98. The company has a market capitalization of $61.01 billion, a price-to-earnings ratio of 19.62, a price-to-earnings-growth ratio of 1.43 and a beta of 0.77.

Humana (NYSE:HUMGet Rating) last posted its quarterly earnings data on Wednesday, July 27th. The insurance provider reported $8.67 EPS for the quarter, beating the consensus estimate of $7.67 by $1.00. Humana had a net margin of 3.52% and a return on equity of 18.42%. The business had revenue of $23.66 billion for the quarter, compared to analysts’ expectations of $23.44 billion. During the same period in the previous year, the firm posted $6.89 EPS. The firm’s revenue was up 14.6% compared to the same quarter last year. As a group, equities research analysts forecast that Humana Inc. will post 24.99 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Friday, September 30th will be paid a dividend of $0.7875 per share. This represents a $3.15 annualized dividend and a dividend yield of 0.65%. The ex-dividend date is Thursday, September 29th. Humana’s payout ratio is currently 12.86%.

Insider Activity

In other news, insider Joseph C. Ventura sold 1,226 shares of the stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $506.78, for a total transaction of $621,312.28. Following the completion of the sale, the insider now directly owns 3,930 shares in the company, valued at $1,991,645.40. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.39% of the company’s stock.

Humana Company Profile

(Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Stories

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.